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Abstract
Objective
Data from Ukraine on risk factors for HIV acquisition are limited. We describe the character-
istics of individuals testing for HIV in the main testing centres of the Ukrainian capital Kiev,
including HIV risk factors, testing rates, and positivity rates.
Methods
As part of a larger study to estimate HIV incidence within Kiev City, we included questions
on possible risk factors for HIV acquisition and testing history to existing systems in 4 infec-
tious disease clinics. Data were provided by the person requesting an HIV test using a
handheld electronic tablet. All persons (16yrs) presenting for an HIV test April 2013–
March 2014 were included. Rates per 100,000 were calculated using region-specific
denominators for Kiev.
Results
During the study period 6370 individuals tested for HIV, equivalent to a testing rate of 293.2
per 100,000. Of these, 467 (7.8%) were HIV-positive, with the highest proportion positive
among 31–35 year olds (11.2%), males (9.4%), people who inject drugs (PWID) (17.9%)
and men who have sex with men (MSM) (24.1%). Using published population size esti-
mates of MSM, diagnosis rates for MSM ranged from 490.6to 1548.3/100,000. A higher pro-
portion of heterosexual women compared to heterosexual men reported contact with PWID,
(16% vs. 4.7%) suggesting a bridging in risk between PWID and their sexual partners.
Conclusion
Collection of HIV risk factor information in Kiev, essential for the purposes of developing
effective HIV prevention and response tools, is feasible. The high percentage of MSM
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among those testing positive for HIV, may indicate a significant level of undisclosed sex
between men in national figures.
Introduction
At 37.1 per 100,000, Ukraine has one of the highest HIV diagnosis rates in Europe during 2012
[1] and estimated adult prevalence of 1.1% [2]. Although the first HIV report was in 1987, the
majority of diagnoses of HIV were made from 1995 onwards [3] and, by 2009, the number
diagnosed was more than double that of 2001 [2], with yearly diagnosis rates rising from 12.5
per 100,000 population in 2001 [4] to 37.1 in 2012 [1].
Instrumental to this rapid increase was injecting drug use, with outbreaks of HIV initially
identified in the southern regions of Odessa and Mykolaiv among people who inject drugs
(PWID) [5–7]. However, in more recent years HIV infection attributable to sexual transmis-
sion has increased with the number of diagnoses reported to be due to sex between men and
women overtaking that among PWID [3]. A suggested reason for this increase is the bridging
between PWID and the heterosexual population through male injecting drug users transmit-
ting to their female sexual partners [8].
Furthermore, men who have sex with men (MSM) and commercial sex workers (CSW) [9]
are part of a ‘hidden epidemic’. In particular, MSM as a group, are subject to stigma and dis-
crimination [3, 10], with Ukraine recently considering following the Russian anti-propaganda
bill against distributing information on non-traditional sexual attitudes [11, 12]. Such acts
make MSM less likely to identify as such [9], making appropriate targeted public health inter-
ventions problematic. Based on published literature, including the European MSM internet
survey (EMIS) (0.3%) [13], and work by AIDS Alliance using a social network scale-up
method, population surveys and estimates from other countries (0.9%) [14], estimates of MSM
living in Ukraine ranged from 62,888 to 198,470. Further, a sentinel study in 2011 interviewing
5950 MSM from all regions of Ukraine, estimated an overall prevalence of 6.4%, ranging from
2% in Mykolayiv to 20% in Donetsk [15]. Yet only 152 of 16,872 new HIV diagnoses in 2012
were reported to be among MSM [1], a considerable under-estimate if the aforementioned fig-
ures are to be believed.
In line with WHO testing guidelines [16], free and confidential testing for HIV is accessible
nationwide, with service-initiated screening also available in antenatal settings, prisons, blood
donor facilities and for policy and regulation reasons. In 2012, just over 2 million tests were
conducted in Ukraine overall, a 49% increase on the 1.5 million reported in 2004 [1].
In this study, we sought to collect more information than is currently available about per-
sons presenting for an HIV test in the main testing centres of the Ukrainian capital Kiev, to
establish the feasibility of collecting such data, and estimate HIV testing rates, positivity rates,
and characterise those at risk of HIV. These data are helpful to healthcare planners and, in par-
ticular, for the design of appropriately-targeted healthcare interventions. They are also needed
as part of a larger study to estimate HIV incidence within that region.
Methods
In April 2013 we introduced new methodology for data collection of persons presenting for an
HIV test at the main testing facilities within the City of Kiev, to characterise populations at
risk. These testing facilities consisted of four infectious disease clinics for HIV, collectively
known as the Kiev City AIDS Centre.
HIV Testing in Kiev City
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All adults (16years) presenting or referred for an HIV test at the Kiev City AIDS Centre,
between April 1st 2013 and March 31st 2014 were included. Persons testing as part of antenatal
or blood donation screening were excluded, as different methodologies for estimating HIV
incidence are required for these populations, given that population sizes for these groups are
known.
At the time of an individual’s initial HIV test, limited information is usually collected by the
healthcare provider seeking input from the attendee. Such information included: identification
number, year of birth, residence and reason for test, but no information on probable route of
exposure is explicitly sought. Working with the non-governmental organisation Perinatal Pre-
vention of AIDS Initiative (PPAI) and the AIDS centre, we introduced a short anonymous
questionnaire to be completed at the time of testing by the clinic attendee using a handheld
electronic tablet. Medical staff completed year of birth, sex and identification number before
passing the electronic tablet to the attendee. A short explanation about the questionnaire was
provided and patients were asked to give their consent to continue or to terminate the session.
A set of four short questions followed asking information on residence, risk factors for acquir-
ing HIV, reason for test and testing history. The electronic tablet was chosen to ensure persons
felt comfortable with disclosing high risk behaviours and maintain anonymity.
Ethics statement
The study was part of CASCADE within EuroCoord (www.EuroCoord.net) funded by the
European Union Framework Programme VII. Ethics approval was given by the ethics commit-
tee of the Institute of Epidemiology and Infectious Diseases, Academy of Medical Sciences of
Ukraine, Kiev, Ukraine and the ethics committee of University College London (UCL). The
study was an extension of the current routine surveillance methods already defined in Kiev
City, consent for an HIV test is required from all individuals aged 14 years and over, those
under the age of 14 require parental consent. LAg Avidity testing was performed on residual
samples and no name, address or otherwise identifiable information was available in the analy-
sis file. Only adults (16years) were included within the study, age categories were defined in
the project protocol, which was reviewed and received ethics approval, no persons under the
age of 16 years were included within the study. Patients did not experience any additional pro-
cedures and no additional consent was sought. The short anonymous questionnaire was intro-
duced as routine surveillance to be completed at the time of testing by the clinic attendee using
a handheld electronic tablet. A short explanation about the questionnaire was provided and
patients consented by completing the questionnaire. If patients did not consent they could ter-
minate the session.
Data Management
Data were captured by a remote secure server and downloaded for analysis. Records were de-
duplicated using year of birth, sex, clinic and identification number, with discrepancies sent
back to the laboratory. The identification number was used to match the person’s data with
their HIV test result. All records with incomplete information (year of birth, sex and date of
diagnosis) or where a previous HIV test was positive, and, therefore, where the diagnosis was
not a new one, were removed. Data are presented for persons aged 16 years and over by age
quartiles.
Probable route of exposure was determined based on the attendee’s answer to the following
questions: ever injected drugs, ever had sex with a person of the opposite sex, ever had sex with
a person of the same sex, ever paid for sex, and ever been paid for sex. Persons with more than
one reported risk factor were classified by the following hierarchical order: PWID, MSM, then
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heterosexual contact. Additional information was available on sexual behaviour (ever paid for
sex, ever been paid for sex or partner of a PWID).
Reason for test was grouped into the following three categories: clinical indication (persons
presenting with symptoms), high risk population (those regarded to engage in high risk behav-
iour i.e. injecting drugs, contact of a known HIV-positive person, those diagnosed with a sexu-
ally transmitted infection, those who experienced an occupational HIV risk, and those
reporting sex with multiple partners), and general screening (before surgical interventions,
recruitment in to the army, prisoners and persons requiring an HIV test due to regulations or
policy, e.g. for employment or visa procurement). Persons with more than one reported reason
for test were classified by the following hierarchical order: general screening, clinical indication,
and high risk population.
Persons were classified as repeat testers if there was evidence of at least one previous nega-
tive HIV test. Persons were excluded if the previous test was within a month of the current
test, if the previous test result was not reported or was equivocal, or if no previous test date was
reported.
Rates per 100,000 population were calculated for HIV tests and HIV diagnoses. Region spe-
cific denominators for Kiev City were based on data collected through the government census
[17].
Population data for MSM, were based on work by the AIDS Alliance [14] and the European
MSM internet survey (EMIS) [13]. The AIDS Alliance used the method of ‘anonymous friend’,
whereby persons were asked to list the behaviours of friends, as well as data from behaviour
studies conducted among at risk populations and sociological surveys. EMIS estimated popula-
tion rates using the diagnosis rate for the Ukraine, the number of survey members, and those
survey members diagnosed with HIV.
Statistical Analysis
Descriptive statistics are given for persons presenting for an HIV test. Using logistic regression
models, we investigated the effect of the following variables on being a repeat tester: age, sex,
residence (Kiev City, Outside Kiev City), probable route of exposure (heterosexual, MSM,
PWID) and reason for test (clinical indicators, general public screening, high risk behaviour).
Two-way interactions were examined.
Statistical analyses were performed using STATA version 13 (STATA Corp, College Station,
TX, USA). Only samples from individuals aged 16 years and over were included in analysis.
Results
During the 12-month period April 2013 –March 2014, 6402 persons were tested for HIV.
Thirty-two were excluded as follows: 7 records were missing year of birth, sex or identification
number, and 25 persons were already known to be HIV positive.
The remaining 6370 tests (3425 in men and 2945 in women) gave a crude test rate of 293.2
per 100,000 population (aged16 years) (Table 1). The median age at test was 30 years (IQR:
26–36), with the majority seeking testing due to symptoms. HIV test results could not be linked
for 353 persons. Of the remaining 6017 tests with a result, 467 (7.8%) were HIV positive, equiv-
alent to a diagnosis rate of 21.5 per 100,000 persons (Table 1). The completion rate for ques-
tionnaires was 99.4% with only 39 persons not providing any further information.
Probable route of exposure to HIV was available for 5986 of the 6017 (99.5%) individuals
with a test result, the majority (4803; 80.2%) of whom reported heterosexual contact, with 191
(3.2%) identifying as MSM. Of the 4803 reporting heterosexual contact, 519 (10.8%) reported
contact with PWIDs, with a higher proportion for women (417/2587, 16.1%) compared to men
HIV Testing in Kiev City
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(101/2216, 4.6%). A further 377 (7.8%) reported paying for sex or reported that they them-
selves were paid for sex.
The median age among those newly-diagnosed was higher than those testing (32 years;
IQR: 28–36), and HIV prevalence among those tested was highest among persons aged 31–35
years, males, PWID and MSM (Table 2). The diagnosis rate for PWID was estimated at 760.7
per 100,000 PWID and, for MSM, ranged from 516.3 to 1548.3 per 100,000 MSM. The propor-
tion of persons newly-diagnosed among those in the heterosexual contact exposure category
was low and similar for men and women. For PWID, the proportion newly-diagnosed was
somewhat higher for women compared with men (21.5% vs. 17.1% respectively).
For 6200 individuals, information on testing history was available, of whom 1413 (23%)
were identified as repeat testers. In univariate logistic regression models, repeat testers were
more likely to be older, MSM or PWID, and where reason for test was high risk behaviour,
compared with first time testers (Table 3). As the interaction between sex and probable route
of exposure was found to be significant (p = 0.004), we re-categorised these two variables to
create a new variable (MSM, female heterosexual contact, male heterosexual contact, female
PWID, and male PWID).
After adjusting for all other variables, probable route of exposure/sex remained an indepen-
dent predictor for repeat testing. Compared to heterosexual women, MSM [Odds Ratio (OR):
1.87; 95% Confidence Interval (CI):1.37–2.55] and PWIDs (males and females) [OR = 1.93;
95% CI:1.62–2.30 and OR = 1.40; 95% CI:1.00–1.96, respectively] were more likely to repeat
test, and heterosexual men were less likely to repeat test [OR = 0.78; 95% CI:0.68–0.91].
Furthermore, repeat testing was significantly more likely with increasing age [OR = 1.28 per
10 year increase, 95% CI:1.19–1.39] and among those engaging in high risk behaviour
[OR = 1.55; 95% CI:1.37–1.76] compared with those testing due to clinical indicators. Repeat
testing was less likely among those testing as part of screening [OR = 0.28; 0.20–0.38] and
those resident outside the City [OR = 0.66; 95% CI:0.52–0.84] (Table 3).
Heterosexual women reporting high risk behaviour (high risk partner or sex work) had a
higher proportion of repeat testers than heterosexual men overall (25%; 135/539 vs. 19%; 72/
374), predominately led by women with partners who inject drugs (28%; 119/420).
Discussion
We estimate an HIV prevalence of 7.8% for persons presenting for an HIV test in Kiev City,
equivalent to 21.5 diagnoses per 100,000 population, and an overall testing rate of 293.2 per
100,000 population. For the first time detailed information on HIV risk behaviour was avail-
able, indicating that MSM and PWIDs were disproportionately affected by HIV. Furthermore,
Table 1. HIV testing and diagnosis rates (per 100,000 population) for persons seeking testing April 2013–March 2014 in Kiev City, Ukraine.
Characteristics Population
[17]
Number requesting HIV
test *
HIV testing
rate
Number newly diagnosed with
HIV
Rate of New
diagnoses
Total 2,172,448 6370 293.2 467 21.5
Age (years) 16–25 484,839 1466 302.4 64 13.2
26–30 212,340 1795 845.3 120 56.5
31–35 177,968 1456 818.1 154 86.5
36 1,297,301 1653 127.4 129 9.9
Sex Male 990,412 3425 345.8 303 30.6
Female 1,182,036 2945 249.1 164 13.9
* Excluding 32 persons: 7 records were missing year of birth, sex or identiﬁcation number, and 25 persons were already known to be HIV positive.
doi:10.1371/journal.pone.0137062.t001
HIV Testing in Kiev City
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given the proportions among newly-diagnosed female heterosexuals reporting sexual contact
with PWID there is further evidence of bridging in risk between PWID and their sexual
partners.
Although, the diagnosis rate of 21.5 per 100,000 population in Kiev City is lower than that
for Ukraine as a whole (37.1 per 100,000), it is however, substantially higher than rates for
Western and Central Europe (6.6/100,000 and 2.1/100,000)[1]. Using MSM population esti-
mates [13, 18], the diagnosis rate for MSM ranged from 490.6/100,000 to 1548.3/100,000. This
is substantially higher than the diagnosis rates of 76.6 to 241.7/100,000 suggested by the 152
Table 2. Distribution of all persons testing for HIV and persons newly diagnosed at any one of the four HIV testing sites between April 2013 –
March 2014 in Kiev City, Ukraine.
Number tested for HIV Number where test result available Newly Diagnosed
N = 63706¼ N = 6017 N = 467 %
Age (years)
25 1466 1381 64 4.6
26–30 1795 1698 120 7.1
31–35 1456 1376 154 11.2
36 1653 1562 129 8.3
Sex
Male 3425 3224 303 9.4
Female 2945 2793 164 5.9
Residence
Kiev (city) 5771 5457 391 7.2
Kiev area (small town) 412 384 53 13.8
Kiev area (village) 111 108 10 9.3
Another area of Ukraine 46 43 7 16.3
Not Reported 30 25 6
Probable route of exposure *
Persons who inject drugs: Male 835 801 137 17.1
Persons who inject drugs: Female 198 191 41 21.5
Men who have sex with men 201 191 46 24.1
Heterosexual contact: Male 2370 2216 114 5.1
Heterosexual contact: Female 2728 2587 122 4.7
Not reported 38 31 7
Testing history
Repeat tester 1413 1365 84 6.2
First-time tester 4787 4499 349 7.8
Not Reported 170 153 34
Reason for test *
Clinical Indicators 3166 2336 257 11.0
High Risk Behaviour 2427 2977 163 5.5
General Public Screening 735 668 40 6.0
Not Reported 42 36 7
* Persons with more than one reported risk factor were classiﬁed by the following hierarchical order: PWID, MSM, then heterosexual contact. Persons
with more than one reported reason for test were classiﬁed by the following hierarchical order: general Screening, clinical indication, then high risk
population.
6¼ Excluding 32 persons: 7 records were missing year of birth, sex or identiﬁcation number, and 25 persons were already known to be HIV positive.
doi:10.1371/journal.pone.0137062.t002
HIV Testing in Kiev City
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MSM diagnosed in Ukraine overall [1], though the prevalence of MSMmay differ between
Kiev and the rest of Ukraine.
Interestingly, there was little difference in the diagnosis rates between men and women
reporting heterosexual contact. Given the high rates of stigma and discrimination within
Ukraine we had anticipated non-disclosure of homosexuality to be high, with men more
likely to report sex with women, leading to high HIV diagnosis rate in heterosexual men com-
pared to heterosexual women. However, this was not reflected in the data, suggesting that
any non-disclosed homosexuality among men is unlikely to be substantial. However, in
agreement with previous findings, our data suggest a bridging between high risk individuals
and the heterosexual population with an estimated 1 in 6 heterosexual women reporting con-
tact with a PWID [8].
Furthermore, our data indicate an increasing number of women being diagnosed with HIV,
particularly women who inject drugs who are at a higher risk as they are more likely to be sec-
ond on the needle, exchange sex for drugs, subject to gender-based violence and stigma, and
have unsafe sex with an injecting partner [19–21].
Testing patterns among persons presenting for an HIV test in Kiev City are consistent with
the previous literature [22–27], where those at high risk of HIV were more likely to frequently
test, both probable route of exposure (MSM and PWID) and reason for test (high risk behav-
iour) were independently associated with repeat testing. Age was also associated with repeat
testing, which may, in part, be due to younger persons having had less time to test than those
who are older. Around one in three MSM and PWID reported a previous test compared to one
in five among heterosexuals, indicating that persons at risk have some awareness about testing;
this was also evident among heterosexual women with partners who inject drugs.
It is important to bear in mind that data from Kiev City may well not be representative for
the whole of Ukraine, particularly for regions with a lower HIV prevalence such as Chernivtsi,
Ternopilm and Transcarpathian, and our findings may not be generalizable to the rest of the
country. For a better understanding of the epidemic in other regions, we believe it would be
beneficial to consider implementation of our methods across Ukraine. Acceptance rate was
Table 3. Factors associated with repeat testing among persons attending for an HIV test April 2013–March 2014 in Kiev City, Ukraine.
Univariate Multivariate*
OR (95% CI) P value OR (95% CI) P value
Age (per 10 year increase) 1.21 (1.12–1.30) <0.001 1.28 (1.19–1.39) <0.001
Area of residence
Kiev City 1 1
Outside Kiev City 0.67 (0.54–0.85) <0.001 0.66 (0.52–0.84) <0.001
Probable route of exposure
Heterosexual contact: Female 1 1
Heterosexual contact: Male 0.81 (0.70–0.93) 0.78 (0.68–0.91)
MSM 2.16 (1.59–2.93) <0.001 1.87 (1.37–2.55) <0.001
PWID: Female 1.52 (1.09–2.12) 1.40 (1.00–1.96)
PWID: Male 2.10 (1.77–2.50) 1.93 (1.62–2.30)
Reason for test
Clinical Indicators 1 1
General Pubic Screening 0.25 (0.19–0.34) <0.001 0.28 (0.20–0.38) <0.001
High Risk Behaviour 1.52 (1.34–1.72) 1.55 (1.37–1.76)
* Adjusted for all other factors in table.
doi:10.1371/journal.pone.0137062.t003
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high (>99%) among attenders and information on HIV risk behaviour was also available for
>99% of those completing the questionnaire. Population data for MSM was estimated using
the published literature, based on work by the AIDS Alliance [14] or through the use of the
European MSM internet survey (EMIS) [13]. There are definite uncertainties within these esti-
mates, indicated by the range, and with both dependent on self-reported information, and fur-
ther work is needed to establish the true numbers at risk.
This study provides more detailed information on persons testing and those newly diag-
nosed with HIV in Kiev City than had previously been available. It highlights the impact key
populations have on the epidemic, feeding into current work on HIV prevention and response.
We have shown that persons were comfortable with disclosing their risk, in particular men
identifying as MSM. Diagnosis rates among MSM for Kiev City suggest that there may be a sig-
nificant level of undisclosed homosexuality overall in Ukraine [9], further supporting work to
minimise stigma and discrimination.
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